相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models
Nikki DeAngelis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E. Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Bella S. Guerrouahen et al.
FRONTIERS IN ONCOLOGY (2020)
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
Mallika Lala et al.
EUROPEAN JOURNAL OF CANCER (2020)
Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.
Victor Moreno et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.
Emiliano Calvo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
G. V. Long et al.
ANNALS OF ONCOLOGY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Xian Shen et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
Apostolia M. Tsimberidou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials
Georgina V. Long et al.
JAMA ONCOLOGY (2017)
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R. Hui et al.
ANNALS OF ONCOLOGY (2017)
Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma
X. Wang et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Using Model-Based Learn and Confirm to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial
J. Elassaiss-Schaap et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
M. Ahamadi et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
G. Bajaj et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
M. Chatterjee et al.
ANNALS OF ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
Kim A. Reiss et al.
IMMUNOTHERAPY (2014)
Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor ( FcRn) Binding
Jan Terje Andersen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Eszter Lazar-Molnar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Variability and inequity in testing of somatic tissue for hereditary cancer: a survey of UK clinical practice
C. L. Gaff et al.
CLINICAL GENETICS (2006)
Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy
A Loskog et al.
LABORATORY ANIMALS (2005)
Crystallization and preliminary X-ray analysis of the complex between human CTLA-4 and B7-2
XW Zhang et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2001)
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex
JCD Schwartz et al.
NATURE (2001)
分享论文
